Condition: Relapsing Multiple Sclerosis · Sponsor: TG Therapeutics, Inc.
The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as measured by T1 Gd-enhancing lesions in participants who had a suboptimal experience on prior anti-CD20 therapy in Part C. The study consists of 3 parts: Part A is single-armed and open-label, Part B is randomized, double-blind, placebo-controlled, and Part C is single-armed and open-label.
This description comes directly from the study's public registry record.
TG Therapeutics Clinical Support Team · 1-877-575-8489 · clinicalsupport@tgtxinc.com
Always discuss trial participation with your own doctor first.
| TG Therapeutics Investigational Trial Site | Birmingham, Alabama, United States | Recruiting |
| TG Therapeutics Investigational Trial Site | Cullman, Alabama, United States | Recruiting |
| TG Therapeutics Investigational Trial Site | Orange, California, United States | Recruiting |
| TG Investigational Site | Fort Collins, Colorado, United States | Recruiting |
| TG Therapeutics Investigational Trial Site | Washington D.C., District of Columbia, United States | Recruiting |
| TG Therapeutics Investigational Trial Site | Tampa, Florida, United States | Recruiting |
| TG Therapeutics Investigational Trial Site | Savannah, Georgia, United States | Recruiting |
| TG Therapeutics Investigational Trial Site | Chicago, Illinois, United States | Recruiting |
| TG Therapeutics Investigational Trial Site | Indianapolis, Indiana, United States | Recruiting |
| TG Therapeutics Investigational Trial Site | Iowa City, Iowa, United States | Recruiting |
| TG Therapeutics Investigational Trial Site | Overland Park, Kansas, United States | Completed |
| TG Therapeutics Investigational Trial Site | Lutherville, Maryland, United States | Recruiting |
+ 35 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05877963